Five-Year Survival Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Metastatic Non–Small-Cell Lung Cancer in CheckMate 227Julie R. Brahmer, Suresh S. Ramalingam, Lorena Lupinacci et al.|Journal of Clinical Oncology|2022Cited by 375
Mesenchymal Stem Cells Promote Mammosphere Formation and Decrease E-Cadherin in Normal and Malignant Breast CellsAnn H. Klopp, Wendy A. Woodward, Lara Lacerda et al.|PLoS ONE|2010Cited by 175
Nivolumab treatment beyond RECIST‐defined progression in recurrent or metastatic squamous cell carcinoma of the head and neck in CheckMate 141: A subgroup analysis of a randomized phase 3 clinical trialRobert I. Haddad, Robert L. Ferris, Fernando Concha‐Benavente et al.|Cancer|2019Cited by 98